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Abstract
Purpose Celiac disease (CD) serology requires analysis
of tissue transglutaminase type-2 (TG2autoAbs), deami-
dated gliadin (DGAbs), and as reference endomysial
autoantibodies (EmA). Total IgA assessment helps to
determine IgA-deficient CD patients. The novel multiplex
indirect immunofluorescence (IIF) technique CytoBead
was used to develop the first quantitative one-step sero-
logical CD assay comprising both simultaneous IgA
autoAb and total IgA testing.
Methods CytoBead CeliAK detecting TG2autoAb,
DGAb, EmA, and simultaneously total IgA uses fluores-
cent microparticles for antigen and antibody immobiliza-
tion along with monkey-esophagus tissue sections on glass
slides. The assay was interpreted visually by classical flu-
orescent microscopy and digital IIF using AKLIDES.
Overall, 380 samples (155 CD patients, 5 with IgA defi-
ciency, 68 with cystic fibrosis, 59 with eye disease, 93
blood donors) were run for performance analysis. Data
were compared with classical IgA autoAb analysis by
ELISA and IIF.
Results Comparing CD-specific IgA autoAb testing by
CytoBead with classical IIF and ELISA, very good
agreements for EmA, TG2autoAb, and DGAb were
determined (Cohen’s j = 0.98, 0.96, 0.85, respectively).
The difference between multiplex and single testing
revealed a significant difference for TG2autoAb testing
only (McNemar, p = 0.0078). Four CD patients and 4
controls demonstrated TG2autoAb positivity by ELISA but
were negative by CytoBead. Further, 140/155 (90.9 %) CD
patients demonstrated TG2autoAb levels above ten times
the upper normal and all five IgA-deficient samples IgA
levels\0.2 g/L by CytoBead.
Conclusions The novel multiplex CytoBead CeliAK
enables simultaneous CD-specific autoAb and IgA defi-
ciency analyses comparable with classical testing by sin-
gle-parameter assays. Thus, comprehensive CD serology
by CytoBead can alleviate the workload in routine
laboratories.
Keywords Celiac disease  Tissue transglutaminase 
Endomysial antibody  Deamidated gliadin  Digital
fluorescence
Introduction
Celiac disease (CD) is a gluten-related and immune-me-
diated small intestinal disease which causes chronic
inflammatory lesions leading to villous atrophy and
hyperplasia of intestinal crypts [1, 2]. The destructive
mucosal changes cause malabsorption in severe cases [3].
The disease demonstrates a strong human leukocyte
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antigen (HLA) association and manifests mainly in HLA-
DQA1*05-DQB1*02 (DQ2) or DQA1*03-DQB1*0302
(DQ8)-haplotype-positive patients [4, 5]. In general, the
inflammatory process in CD is characterized by an
increased intraepithelial lymphocyte count with values
greater than 25/100 cells [6]. Celiac disease can occur from
the second half of the first life year throughout life time
with asymptomatic intermediate stages particularly in adult
patients and differing clinical symptoms [7, 8]. High
prevalences of CD have been reported in Caucasians: 1 in
99 in Finland, 1 in 122 in Northern Ireland and 1 in 175 in
Italy [9–12].
The diagnosis of CD comprises clinical, serological, and
histological findings and is confirmed by normalization of
pathological findings under a gluten-free diet in the
majority of patients [8, 13]. Serology is paramount for the
diagnosis of CD requiring the detection of autoantibodies
(autoAbs) to endomysium (EmA), deamidated gliadin
(DGAb), and tissue transglutaminase type 2 (TG2autoAb)
of the IgA isotype [14–16]. Due to the high specificity of
EmA results obtained by indirect immunofluorescence
(IIF) testing, this autoAb is still regarded as the reference
standard for CD-specific Ab detection [8]. However, clas-
sical IIF reading may be subject to interobserver and sub-
strate-related variability which favors the testing of IgA
autoAb to TG2 by immunometric solid-phase assays such
as enzyme-linked immunosorbent assay (ELISA) instead
[8, 17]. Of note, 2.6 % of CD patients suffer from IgA
deficiency and may present non-classical CD complicating
the diagnosis of CD [18, 19]. In contrast, up to 7.7 % of
children with IgA deficiency may have CD [20]. Note-
worthy, selective IgA deficiency being the most common
primary immunodeficiency disorder with approximately 1
case in 400 humans is associated with DQ2, too. Thus,
analysis of CD-specific IgG has been recommended in the
case of IgA-deficient subjects with CD (total serum IgA
\0.2 g/L) [21, 22].
Novel diagnostic criteria have been developed by the
European Society for Paediatric Gastroenterology, Hepa-
tology and Nutrition (ESPGHAN) recently strengthening
the role of CD serology [8]. Accordingly, the diagnosis of
CD can be confirmed without histology in case of
TG2autoAb IgA levels 10 times higher than the upper limit
of normal (ULN) in patients positive for HLA-DQ2 or DQ8
and a positive response to gluten-free diet.
Consequently, taking into account the number of tests
required for an appropriate CD serology, there is a need for
new strategies to reduce the workload and laboratory costs
in routine laboratories [23–26]. Thus, the aim of this study
was to evaluate a multiplex strategy detecting CD-specific
IgA autoAbs with the novel CytoBead technique which has
been already employed successfully for multiplex autoAb
analysis [27, 28]. The assay allows the simultaneous
analysis of EmA, TG2autoAb, and DGAb as well as the
determination of total IgA in one reaction environment by
IIF for the first time.
Materials and methods
Patients and controls
In total, 380 patients and controls including 155 patients
with de novo CD, 5 with IgA deficiency, 68 with eye
diseases (ED), 59 with cystic fibrosis (CF), and 93 blood
donors (BD) were included. Pediatric patients with CD,
ED, and CF were diagnosed in the Children’s Hospital of
the Medical Faculty of the Technical University Dresden.
Correctness of CD diagnosis was confirmed in all patients
by two investigators (ML and CK). Patient characteristics
are summarized in Table 1. Serum samples were stored at
-20 C until use.
The study was approved by the Local Ethics Committee
(EZ151052010) and conducted in accordance with the
Helsinki declaration.
CD-specific Ab testing by classical IIF and ELISA
Anti-endomysium IgA was analyzed by IIF employing
cryostat sections of monkey esophagus according the rec-
ommendations of the manufacturer (GA Generic Assays
GmbH, Dahlewitz, Germany) and reported elsewhere [24].
Processed slides were read either visually by fluorescent
microscopy or with the automated interpretation system
AKLIDES (Medipan GmbH, Berlin/Dahlewitz, Ger-
many) [24, 29].
IgA TG2autoAb and DGAb were determined by com-
mercially available enzyme-linked immunosorbent assays
(ELISAs) according to the recommendations of the man-
ufacturer (GA Generic Assays GmbH) as described else-
where [24]. Absorbance was read in a microplate reader at
450 nm and results were expressed in arbitrary units per
milliliter (U/mL) according to the standards provided.
CD-specific Ab and IgA deficiency testing
by CytoBead immunoassay
The CytoBead CeliAK immunoassay (GA Generic Assays
GmbH) uses a combination of monkey-esophagus cryostat
tissue sections and autoantigen-coated fluorescent
microbeads (Red 550, excitation 610 nm and emission
690 nm; sizes 9, 15 lm; PolyAn GmbH, Berlin, Germany)
on slides with compartmented wells for simultaneous
autoAb analysis (Fig. 1). The 9-lm beads were covalently
coated with recombinant TG2 (DiaRect AG, Freiburg,
Germany) and the 15-lm beads with recombinant DG
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(DiaRect) or sheep antihuman IgA antibody (Seramun
Diagnostica GmbH, Heidesee, Germany). To create one
common reaction environment with the immobilized cry-
opreserved esophagus tissue in the middle compartment,
antigen- and Ab-coated beads were immobilized in the
peripheral compartments together with reference beads
(12 lm, dye rhodamine, excitation at 526 nm and emission
at 555 nm) supporting the following beneficial assay
characteristics: (1) focusing and orientation in the left and
right parts of the well, (2) discrimination of 9-lm TG2-
coated beads from 15-lm DG-coated beads in case of a
positive autoAb reaction to TG2 and/or DG, and (3) pro-
viding focal point to check for IgA deficiency. Thus, TG2-
and DG-coated fluorescent beads as well as reference beads
were immobilized in the left-hand and antihuman IgA Ab-
coated and reference beads in the right-hand well sections.
In the case of a non-sufficient number of beads, automated
evaluation by AKLIDES does not analyze the result.
Briefly, diluted patient samples at a dilution of 1:10
were incubated for 30 min at room temperature. Unbound
Table 1 Characteristics of
patients and control cohorts




Celiac disease 155 56 99 6 (8) 9 (13)
Age\18 131 50 81 6 (8) 6 (9)
Age C18 24 6 18 31 (24) 32 (17)
IgA deficiency 5 3 2 17 (13) 7 (4)
Cystic fibrosis 59 26 33 13 (22) 11 (23)
Eye diseases 68 43 25 6 (4) 6 (3)
Blood donors 93 44 49 23 (2) 23 (4)
IQR interquartile range
Fig. 1 Multiplex reaction environment of the CytoBead CeliAk for
the simultaneous analysis of celiac disease (CD)-specific IgA
autoantibodies and IgA deficiency. Employing compartmented wells
on classical indirect immunofluorescence (IIF) glass slides, tissue
transglutaminase type 2 (TG2)- and deamidated Gliadin (DG)-coated
fluorescent beads as well as reference beads were immobilized in the
left-hand well section. Further, cryopreserved tissue sections of
monkey esophagus were fixed in the middle section for classical
endomysial antibody (EmA) analysis by IIF as well as antihuman IgA
antibody-coated and reference beads in the right-hand well sec-
tion. Exemplary, the well demonstrates a typical finding of a serum
from a patient with CD by showing the classical EmA pattern on
monkey esophagus in the middle section and a positive fluorescent
halo of TG2-coated beads in the left-hand as well as of anti-IgA beads
in the right-hand sections. Reference beads aid in distinguishing TG2-
coated beads from DG-coated ones and orientation by visual
evaluation with fluorescence microscope
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serum components were removed by a subsequent wash
cycle. The second incubation of sheep antihuman IgA
conjugated to fluorescein isothiocyanate (FITC) (Seramun
Diagnostica) for 30 min at room temperature was followed
by another wash cycle to remove excess secondary Ab-
conjugate molecules.
After mounting, slides were subjected to visual inter-
pretation under a fluorescence microscope equipped with a
FITC filter (excitation 495 nm; emission 519 nm,
EUROStar, Euroimmun AG, Lu¨beck, Germany) at a
magnification of 1009 and to automated analysis using the
digital imaging platform AKLIDES. For confirmation of
EmA positivity, a higher magnification of 4009 was
deployed. A serum is considered positive for EmA if a
clearly discernible fluorescent pattern in the Muscularis
mucosae (staining of the endomysium around the smooth
muscle fibers) has been detected.
A positive reaction of CD-specific autoAb or serum IgA
at the concentration of 0.2 g/L or higher revealed a green-
emitting halo on the microbeads which can be readily
discriminated from the homogeneous fluorescence of the
reference beads (Fig. 1).
Fluorescent signals of EmA patterns and TG2-, DG- or
anti-IgA-coated beads were categorized semi-quantita-
tively as negative (-), borderline (;), weak positive (1?),
medium positive (2?), or strong positive (3?).
For automated evaluation, digital image taking was
performed on tissue sections of monkey esophagus first
using diamidino phosphatidyl inositol (DAPI) added to the
conjugate buffer for image focusing on cell nuclei as
reported elsewhere [29, 30]. After switching into the FITC
channel, nine images were taken and merged into an
overview picture by the AKLIDES software which was
used for EmA analysis by the observer afterwards.
Subsequently, focusing and classification of the
microbeads according to size and fluorescence intensity
was run including the measurement of the green fluores-
cence (halo) intensity of positive signals. The latter inten-
sity is directly proportional to the amount of autoAb or
serum IgA bound. Results were read quantitatively in
arbitrary U/mL by employing master standard curves for
each parameter. Of note, the reference beads are not nec-
essary for automated evaluation but only for bead-size
differentiation during visual reading. Obtained fluores-
cence images and corresponding quantitative data were
stored in lossless compressed tagged image file (TIF) for-
mat (Fig. 2).
Statistical analysis
The D’Agostino–Pearson test was employed to check for
normal distribution. The Kruskal–Wallis test was used for
analyzing the difference among patient and control groups.
Inter-rater agreement statistics (Cohen‘s kappa, j) and
McNemar’s test were employed for testing the concor-
dance of different techniques. p values below 0.05 were
considered significant. Receiver operating characteristics
(ROC) curve analysis was performed like all other tests
using MedCalc software (MedCalc, Mariakerke, Bel-
gium; Version 12.4.0).
Fig. 2 Workflow for automated
reading of CytoBead CeliAK
tests with the AKLIDES system.
1 Focusing of monkey-
esophagus tissue sections in the
DAPI channel and subsequent
image taking in the FITC
channel in the central
compartment. 2 Focusing and
classification of the microbeads
according to size and
fluorescence intensity and
subsequent analysis of the green
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Results
Cutoff determination of CD-specific autoAb testing
To determine the cutoffs of the CytoBead CeliAK for IgA
CD-specific autoAb, CD patients (n = 155) and control
sera (n = 220) were run on the automated IIF interpreta-
tion system Aklides. ROC curve analysis revealed the
following optimal cutoffs for TG2autoAb and DGAb
testing: 3.91 U/mL and 2.89, respectively. For practical
DGAb analysis, a higher cutoff of 5.0 was used which
corresponds to a specificity of 97.2 % instead of 93.5 %.
Sensitivity dropped from 87.6 to 75.2 % accordingly.
In line with the new CD diagnosis criteria, 109 ULN of
IgA TG2autoAb can be used for the diagnosis of CD
avoiding duodenal biopsy. The ULN represents the mean
autoAb value of non-diseased subjects plus two standard
deviations. Thus, we determined the ULN for two different
age groups of CD patients younger (n = 130) and 18 years
and older (n = 24) (Table 2). Since both control groups
(pediatric patients with ED and BD, respectively) did not
show normality, the corresponding 97.5 % percentiles were
determined instead. Altogether, the obtained values were
compared to the cutoffs obtained by ROC curve analysis.
The IgA TG2autoAb cutoffs for the two different CD age
groups and all CD patients revealed an optimal area under
the curve of 1.0, respectively, indicating 100 % specificity
and sensitivity regarding the cohorts used for ROC curve
calculations. Remarkably, ULN, 97.5 % percentiles, and
cutoffs obtained by ROC curve analysis demonstrated
different values whereas the latter were at least 1.5 times
higher than the respective ULN (Table 2).
Intra-assay and inter-assay coefficient of variation
analysis
The intra-assay and inter-assay coefficients of variation
(CV) were analyzed using reference sera with the
corresponding autoAb specificities. Intra-assay CV was
determined by eight measurements for each serum while
inter-assay CV was assessed by analyzing eight determi-
nations for each serum on five different days in accordance
with the CLSI protocol EP15-A2.
The intra-assay CV of the CytoBead CeliAK assay for
CD-specific autoAb to TG2 and DG ranged from 1.5 to
9.5 % and inter-assay CV from 1.4 to 11.5 % (Table 3).
Analysis of IgA deficiency by CytoBead CeliAK
The presence of IgA deficiency was evaluated visually by
the lack of a fluorescent signal (halo) on antihuman IgA-
coated microbeads in the CytoBead CeliAK. All 5 IgA-
deficient samples (IgA\0.2 g/L) were scored negative by
visual evaluation. Out of the remaining 375 patient and
control samples 374 revealed a positive fluorescence on the
antihuman IgA microbeads. The patient suffering from ED
and Dandy–Walker syndrome with negative fluorescence
was confirmed by nephelometry as IgA deficient.
Quantitative IgA testing by CytoBead CeliAK demon-
strated for all five IgA-deficient samples IgA levels below
0.2 g/L. Like visual examination, automated IgA analysis
scored 374/375 patient and control samples as IgA suffi-
cient with IgA levels above 0.2 g/L (Suppl. Fig. 1).
CD-specific autoAb analysis by CytoBead CeliAK
In total, 380 serum samples were analyzed with the
CytoBead CeliAK assay for the detection of EmA on
monkey-esophagus tissue sections by visual examination of
an overview image created by the software and specific
autoAb to TG2 and DG (Table 4). The latter autoAb testing
was performed visually to obtain qualitative results and
automatically for quantitative assessment. Thus, detection
of EmA, TG2autoAb, and DGAb revealed significantly
different levels in the cohorts investigated whereas, as
expected, patients with CD demonstrated significantly
Table 2 Upper limit of normal
(ULN), 97.5 % percentiles and
cutoffs for autoantibody
(autoAb) testing to tissue
transglutaminase 2 (TG2)
ULN (U/mL) 97.5 % percentile (U/mL) Cutoff (U/mL)
ED (n = 68) 1.65 1.94 3.91a
BD (n = 91) 1.15 1.42 1.71b
ED ? BD (n = 159) 1.41 1.54 3.91c
TG2autoAb were determined by CytoBead CeliAK in 130 pediatric/adolescent patients with celiac disease
(CD) (\18 years) and 24 adult patients (C18 years) as well as pediatric patients with eye disease (ED) and
blood donors (BD) and subjected to receiver operating characteristics curve analysis. ULN (mean ? 2
standard deviations), 97.5 % percentiles, and cutoffs were calculated. Total sample numbers can differ due
to lack of human material or assay failure
a ROC: CD\18 years vs ED
b ROC: CD C18 years vs BD
c ROC: CD vs ED ? BD
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higher levels than patients with ED and CF as well as BD
(Kruskal–Wallis test, p\ 0.001, respectively; see Suppl.
Fig. 2).
Regarding TG2autoAb and DGAb prevalence, there was
no statistical difference between visual qualitative and
automated quantitative analysis by AKLIDES,
respectively. Furthermore, there was no statistical differ-
ence in EmA prevalences detected by visual classical and
CytoBead reading. However, visual examination of fluo-
rescence halos on the antigen-coated beads by visual
observation revealed more positives for TG2autoAb (154/
155 vs 150/154) and DGAb (124/155 vs 115/153) testing in
Table 3 Assay performance of the CytoBead CeliAK assay
Day TG2autoAb (U/mL) DG Ab (U/mL) Total IgA (g/L)
1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
Intra-assay variance
68.6 69.5 67.6 70.2 69.0 49.2 35.6 41.7 44.0 41.6 0.32 0.29 0.28 0.29 0.27
SD 4.3 1.8 2.6 3.2 1.1 3.4 3.4 2.6 1.8 2.9 0.02 0.02 0.02 0.02 0.02
CV % 6.3 2.6 3.8 4.5 1.5 6.9 9.5 6.2 4.0 6.9 6.2 6.9 7.1 6.8 7.4
Inter-assay variance days a–e
68.9 42.4 0.29
SD 0.9 4.9 0.01
CV % 1.4 11.5 6.4
Autoantibodies (autoAb) to tissue transglutaminase type 2 (TG2) and deamidated gliadin (DG) as well total serum IgA were determined by
CytoBead CeliAK in reference sera diluted 1–10. Intra-assay and inter-assay (8 times per run over 5 days) coefficients of variation (CV) were
determined in accordance with the CLSI protocol EP15-A2
AU arbitrary units, SD standard deviation
Table 4 Prevalence of celiac disease (CD)-specific IgA autoantibodies (autoAb) by classical indirect immunofluorescence (IIF), enzyme-linked
immunosorbent assay (ELISA) and multiplex CytoBead CeliAK analysis in 380 patients and controls
CD\18 years CD C18 years CD CF ED IgA deficiency BD
n = 131 n = 24 n = 155 n = 59 n = 68 n = 5 n = 93
IIF EmA 130/131 (99.2) 23/23 (100.0) 153/154 (99.4) 0/59 (0.0) 0/68 (0.0) 0/5 (0.0) 2/93 (2.2)
ELISA
TG2autoAb 129/129 (100.0) 23/24 (95.8) 152/153 (99.3) 2/59 (3.4) 0/68 (0.0) 0/5 (0.0) 4/93 (4.3)
DGAb 103/130 (79.2) 16/24 (66.7) 119/154 (77.3) 2/59 (3.4) 1/68 (1.5) 0/5 (0.0) 6/93 (6.5)
At least 1 autoAb positive 129/129 (100.0) 23/23 (100.0) 152/153 (99.3) 2/59 (3.4) 1/68 (1.5) 0/5 (0.0) 6/93 (6.5)
CytoBead CeliAK visual
IIF EmA 128/131 (97.7) 24/24 (100.0) 152/155 (98.1) 1/59 (1.7) 0/68 (0.0) 0/5 (0.0) 1/93 (1.1)
TG2autoAb 130/131 (99.2) 24/24 (100.0) 154/155 (99.4) 3/59 (5.1) 0/68 (0.0) 0/5 (0.0) 2/93 (2.2)
DGAb 102/131 (77.9) 22/24 (91.7) 124/155 (80.0) 3/59 (5.1) 0/68 (0.0) 0/5 (0.0) 4/93 (4.3)
At least 1 autoAb positive 130/131 (99.2) 24/24 (100.0) 154/155 (99.4) 3/59 (5.1) 0/68 (0.0) 0/5 (0.0) 4/93 (4.3)
Automated
TG2autoAb 128/130 (98.5) 22/24 (91.7) 150/154 (97.4) 0/59 (0.0) 0/68 (0.0) 0/5 (0.0) 0/93 (0.0)
DGAb 97/129 (75.2) 18/24 (75.0) 115/153 (75.2) 3/58 (5.2) 0/67 (0.0) 0/5 (0.0) 3/93 (3.2)
At least 1 autoAb positive 128/130 (98.5) 24/24 (100.0) 152/155 (98.1) 3/58 (5.2) 0/67 (0.0) 0/5 (0.0) 3/93 (3.2)
Endomysial antibodies (EmA) as well as autoAb to transglutaminase type 2 (TG2) and deamidated gliadin (DG) were determined by classical IIF
and ELISA, respectively. For comparison, these CD-specific autoAbs were analyzed by multiplex CytoBead testing including simultaneous EmA
analysis on monkey-esophagus tissue sections as well as TG2 and DG autoAb determination using microbeads by either visual qualitative or
automated quantitative AKLIDES interpretation. Total sample numbers can differ due to lack of human material or assay failure
BD blood donors, CF cystic fibrosis, ED eye disease
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patients with CD. Of note, in control cohorts like patients
with CF, visual examination of corresponding beads also
revealed more positives (TG2autoAb 3/59 vs 0/59).
Employing the cutoff of 3.91 U/mL instead of ULN in
accordance with the recommendations of the ESPGHAN,
101 (65.6 %) out of 154 patients with CD demonstrated a
TG2autoAb cutoff ratio above 10 (Fig. 3). Of note, all
controls revealed ratios below 10 for this cutoff value. In
contrast, the highest ULN obtained for children with ED as
controls was only 1.65 U/mL (Table 2). In this case,
134/154 (87.0 %) of CD patients revealed TG2autoAb
levels[109 ULN whereas 13/220 (5.9 %) controls also
did. At the lowest ULN of 1.15 U/mL obtained for BD as
controls only, 140/154 (90.9 %) of CD patients demon-
strated values[109 ULN. Both, the numbers of patients
and controls with TG2autoAb levels[109 ULN compared
to those with[109 cutoff, respectively, were significantly
different using the cutoff obtained by ROC curve analysis
and highest ULN (p\ 0.0002; respectively).
Comparison of CytoBead CeliAK with classical IIF
and ELISA
Comparing automated CD-specific autoAb testing by
CytoBead CeliAK with classical IIF and ELISA analysis, a
very good agreement was established for EmA, TG2au-
toAb, and DGAb determination (Cohen’s j[ 0.8)
(Table 5). There was a significant difference between
CytoBead and classical testing for TG2autoAb only
according to McNemar’s statistics (p = 0.0078). Eight out
of 372 (2.2 %) patients and controls revealed different
TG2autoAb findings. All eight sera demonstrated negative
TG2autoAb levels by CytoBead CeliAK and positive ones
by classical ELISA. Out of these eight sera four belonged
to patients with CD, two to patients with CF and two were
from BD. Three out of the four CD patients also demon-
strated positive EmA findings both by CytoBead CeliAk
and classical IIF.
Altogether, there was no significant difference in the
diagnostic sensitivity (99.4 vs 98.1 %) and specificity (96.9
vs 97.3) taking into account positivity of at least one CD-
specific autoAb by classical and CytoBead testing
(p[ 0.05, respectively).
Discussion
The new diagnostic guidelines presented by ESPGHAN
recently recommend the detection of EmA, TG2autoAb,
and DGAb for the serology of CD [8]. Accordingly, EmA
and histology are still considered the reference methods for
CD and EmA should be used as reference standard for the
validation of CD-specific autoAb tests. Of note, for the first
time, duodenal biopsies can be waived for the diagnosis of
CD in children and adolescents provided TG2autoAb levels
reach values[109 ULN, and patients demonstrate signs
and symptoms suggestive for CD. Further laboratory test-
ing including HLA typing of DQ2/DQ8 positivity or con-
firmation of autoAb positivity by EmA and response to
gluten-free diet are requested. From a routine autoimmune
laboratory perspective, this approach requires the detection
of CD-specific autoAb by different techniques and, hence,
creates constraints to run large numbers of samples cost-
effectively. Furthermore, DGAb are recommended as
additional CD-specific Ab in the serological workup of
patients. Accumulating evidence indicates that in particular
IgG DGAb appears to have an excellent positive predictive
value and their combination with IgA TG2Ab can omit
total IgA assessment [31]. Indeed, total IgA analysis is
required by the guidelines since IgA deficiency is fre-
quently found in patients with CD to prevent false-negative
IgA autoAb findings.
Thus, there is obviously a demand for multiplex meth-
ods to analyze CD-specific autoAb and IgA deficiency
simultaneously in one sample. To the best of our knowl-
edge, the CytoBead technique based on digital fluorescence
is the first assay technology available so far which provides
the unique opportunity to combine autoAb testing
employing tissue and purified antigenic targets in one
reaction environment [28]. Thus, we developed the Cyto-
Bead CeliAK assay for the simultaneous detection of CD-
specific IgA autoAb including the reference autoAb EmA
and total IgA testing using this novel technology. The
efficacy thereof has been demonstrated for similar labora-
tory demands of multiplex autoAb testing like antinuclear
and antineutrophilic cytoplasmic Ab analyses recently [27,
28, 32]. Novel pattern recognition algorithms and digital
fluorescence have paved the way for quantification and
Fig. 3 Ratio of tissue transglutaminase type 2 (TG2) IgA autoanti-
body levels to their cutoff as upper limit of normal (ULN) obtained by
CytoBead CeliAk in 379 patients and controls. BD blood donors, CD
celiac disease, CF cystic fibrosis, ED eye disease
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automation of autoAb testing through IIF interpretation
systems [33–36]. This has ushered in a new era in the
routine autoimmune laboratory for IIF testing with regard
to improved standardization and modern data management
[34, 36–38].
The comparison of CD-specific autoAb testing by
CytoBead CeliAK with classical IIF and ELISA revealed a
very good agreement for EmA and TG2autoAb (Cohen’s
j[ 0.8) as well as a good one for DGAb analysis. Thus,
the serum dilution of 1 in 10 deployed for the CytoBead
assay did not bring about an elevated rate of false-positive
findings in the control groups and showed a satisfactory
sensitivity for EmA. Other CytoBead reaction environ-
ments for the detection of autoAb deploying also lower
dilutions than classical techniques like ELISA have
demonstrated a similar performance [27]. As a fact, the
difference between CytoBead and classical testing was
only significant for TG2autoAb testing. The eight dis-
crepant sera revealing TG2autoAb positivity by ELISA and
negative results by CytoBead CeliAK belonged to four CD
patients and four controls. Thus, IgA TG2autoAb analysis
by CytoBead CeliAK seems to be an appropriate method to
fulfill the requirements by the novel ESPGHAN diagnostic
CD criteria to avoid duodenal biopsy. Indeed, a strong
association of EmA with the presence of CD even irre-
spective of the EmA titre has been reported recently [39].
The majority of EmA-positive CD patients demonstrated
IgA TG2autoAb levels above 109 ULN in our study.
However, we found different values for ULN, corre-
sponding 97.5 % percentiles in case of non-normal distri-
bution, and cutoffs determined by ROC curve analysis.
This resulted even in significantly different numbers of CD
patients and controls with[109 ULN compared to those
with [109 cutoff values, respectively. The novel
diagnostic criteria allow the use of ULN or cutoffs for this
kind of evaluation which can, as shown in our study, lead
to misinterpretations. The application of a common mul-
tiple of ULN in this respect has been criticized elsewhere
calling into question the universal use of this approach
[40]. Thus, we feel that the diagnostic criteria need a
detailed definition thereof in a further update badly.
Instead of testing for IgA TG2autoAb preferentially as
recommended by the new ESPGHAN guidelines, the
simultaneous detection of EmA by CytoBead can be an aid
in case of TG2autoAb findings leading to values below the
respective 109 ULN or 109 cutoff. Of note, all controls
demonstrated values below 109 cutoff in our study. Fur-
thermore, IgA DGAb can further support the serological
diagnosis of CD. The simultaneous detection of IgG
DGAb, which was not demonstrated in this study, however,
can be achieved by the use of antihuman IgG labeled to a
different fluorescent dye and might even further strengthen
this diagnosis as reported elsewhere [31].
Although there was no improvement of the already
high sensitivity of single IgA CD-specific autoAb testing,
the CytoBead technology appears to provide a unique
cost-effective opportunity for multiplex parameter CD
serology. Earlier attempts to multiplex CD-specific
autoAb and total IgA analyses by line immunoassay did
not provide quantitative autoAb testing [24]. To the best
of our knowledge, the CytoBead CeliAK is the first
multiplex quantitative IgA TG2autoAb and DGAb test
which enables additional simultaneous EmA analysis as
reference method and IgA deficiency testing. This com-
prehensive approach may improve the laboratory efficacy
of CD serology. Of note, it can easily incorporate further
CD-specific autoAb such as autoAbs to GP2, which can
stratify CD patients [41–43].
Table 5 Comparison of celiac
disease-specific IgA assessment
by automated multiplex





in 376 patients and controls
without IgA-deficient samples
CytoBead CeliAK Classical IIF Cohen’s ja 95 % CI Difference (%) 95 % CI pb




TG2autoAb Pos Neg 0.96 0.92–0.99 2.15 0.56 to 2.15 0.0078
Pos 150 0
Neg 8 214
DGAb Pos Neg 0.85 0.79–0.91 0.55 -2.27 to 3.23 0.8388
Pos 108 13
Neg 20 231
Autoantibody, autoAb; DG, deamidated gliadin; EmA, endomysial antibody; Neg, negative; Pos, positive
TG2 tissue transglutaminase type 2
a Cohen’s kappa (j B 0.2 poor, 0.21–0.40 fair, 0.41–0.6 moderate, 0.61–0.8 good, 0.81–1.0 very good
agreement)
b McNemar’s test
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